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Currently, single-nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) of >5% are preferentially used in case-control
association studies of common human diseases. Recent technological developments enable inexpensive and accurate genotyping of
a large number of SNPs in thousands of cases and controls, which can provide adequate statistical power to analyze SNPs with MAF
<5%. Our purpose was to determine whether evaluating rare SNPs in case-control association studies could help identify causal SNPs
for common diseases. We suggest that slightly deleterious SNPs (sdSNPs) subjected to weak purifying selection are major players in
genetic control of susceptibility to common diseases. We compared the distribution of MAFs of synonymous SNPs with that of non-
synonymous SNPs (1) predicted to be benign, (2) predicted to be possibly damaging, and (3) predicted to be probably damaging by Poly-
Phen. Our sources of data were the International HapMap Project, ENCODE, and the SeattleSNPs project. We found that the MAF
distribution of possibly and probably damaging SNPs was shifted toward rare SNPs compared with the MAF distribution of benign
and synonymous SNPs that are not likely to be functional. We also found an inverse relationship between MAF and the proportion
of nsSNPs predicted to be protein disturbing. On the basis of this relationship, we estimated the joint probability that a SNP is functional
and would be detected as signiﬁcant in a case-control study. Our analysis suggests that including rare SNPs in genotyping platforms will
advance identiﬁcation of causal SNPs in case-control association studies, particularly as sample sizes increase.Introduction
The common-disease common-variant (CDCV) hypothe-
sis1–4 has been the prevailing paradigm for case-control
association studies for the past decade. Although the
CDCV hypothesis1 originally deﬁned common polymor-
phisms as those with a population frequency of R1%, in
practice researchers often exclude single-nucleotide poly-
morphisms (SNPs) that have frequencies <5% from case-
control association studies. The International HapMap
Project was designed to improve the efﬁciency of case-
control association studies and intentionally targeted
SNPs with minor allele frequencies (MAFs) of R5%.5,6
Common SNPs (SNPs with MAF R5%) are preferentially
queried in most case-control association studies for two
major reasons: (1) the statistical power is not sufﬁcient
for rare SNPs when sample sizes are limited, and (2) com-
mon SNPs can signiﬁcantly contribute to disease preva-
lence even if their effect on disease risk is modest.
Case-control association studies have led to the identiﬁ-
cation of several polymorphisms that affect a person’s risk
for common diseases, including Alzheimer’s disease
(APOE),7 type 2 diabetes (PPARG and KCNJ11),8–10 and
several others.11–14 Furthermore, several common SNPs
affecting cancer susceptibility have been identiﬁed.15–18
However, many of these currently identiﬁed SNPs have
modest effects on cancer risk and have low reproduci-
bility.19–23
It is also noteworthy that most of the cited studies were
conducted with relatively small study samples (400–1000100 The American Journal of Human Genetics 82, 100–112, Januarstudy subjects). Recent technological advances enable
genotyping of hundreds of thousands of SNPs in thou-
sands of cases and controls (e.g., 24 and 25). A large sample
size allows SNPs with MAF <5% to be analyzed. The dom-
inance of the CDCV hypothesis has dissuaded genotyping
companies from including rare SNPs in coding and pro-
moter regions in their SNP genotyping panels. In this anal-
ysis, we evaluated the hypothesis that in large case-control
association studies, targeting SNPs with MAF <5% is likely
to be more effective than targeting common SNPs in de-
tecting genetic susceptibility to common diseases, includ-
ing cancer.
Material and Methods
Data Retrieval
We used the International HapMap database (rel22_Build36)26 to
retrieve data on the distribution of MAFs for SNPs annotated as
intronic, synonymous, or nonsynonymous by the dbSNP data-
base.27,28 The HapMap data are subdivided into three groups or
samples by race: whites of North European origin, Asians (Chinese
and Japanese), and Yoruba in Ibadan, Nigeria. In this study, we sep-
arately analyzed CEPH and Yoruba samples because there is con-
siderable variation in allele frequencies between them.29–31 We
did not include Chinese and Japanese samples because different
sample sizes were queried: If analyzed separately, the sample size
is lower than those for CEPH and Yoruba; if combined, the sample
size is bigger. A separate analysis was run with SNPs data from the
ENCODE project.32 We obtained the ENCODE data by sequencing
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novel SNPs detected by sequencingwere then genotyped in all 269
HapMap DNA samples.32
Data from the dbSNP database were used for the analysis of the
relationship between MAF and the proportions of nsSNPs pre-
dicted to be protein disturbing. Not all SNPs reported in the dbSNP
are true polymorphisms; according to some studies, the false-dis-
covery rate might be as high as 10%.33,34 To decrease the propor-
tion of false discoveries in our sample, we used only frequency-val-
idated SNPs. Thus, 6158 frequency-validated nsSNPs from 3912
genes were used in the analysis.
SeattleSNPs Database
The SeattleSNPs project generated SNP data for samples from
both European and African populations. At the time of our access
(August 2007), the database contained sequencing data from 307
genes ranging in length from 3 Kb (ICAM4 gene) to 653 Kb
(SEC15L2 gene). The SNP data were available for 24 African
descent (AD) and 23 European descent (ED) subjects. The total
number of SNPs detected in the analysis included 31505 in-
tronic, 764 synonymous, and 720 nonsynonymous SNPs. We
did not include deletions, insertions, and sites with more than
two alleles in the analysis. The SNPs were identiﬁed by sequenc-
ing of genomic DNA and, therefore, provide unbiased representa-
tion of different types of SNPs in gene regions. Because the
number of nonsynonymous SNPs was low in this sample, we
subdivided SNPs in ten MAF categories with increments of 5%.
Nonsynonymous SNPs were subdivided into two groups: (1)
benign (B) and (2) possibly or probably damaging SNPs
(Pos.D./Prob.D.). We combined the possibly and probably dam-
aging SNPs together because overall there were only 214 damag-
ing SNPs.
Intronic Ratio
We used the ratio of absolute numbers of nsSNPs to the absolute
number of intronic SNPs in a given MAF bin (intronic ratio) to vi-
sualize the effect of purifying selection.35 A constant intronic ratio
suggests that there are no differences in the intensity of purifying
selection among MAF bins. Counts of the SNPs of different MAF
categories for HapMap and SeattleSNPs samples are shown in
Tables 1 and 2.
Prediction of Functional SNPs
NsSNPs that are likely to disturb protein structure or function can
be predicted with bioinformatics approaches. Several bioinfor-
matics tools for predicting the functionality of nsSNPs have
been developed.36–38 In this study, we used SIFT and PolyPhen
to evaluate the functional signiﬁcance of SNPs because those
methods are the most frequently used.36 SNPs predicted to be in-
tolerant by SIFTwere considered functional, and SNPs predicted to
be tolerant were considered nonfunctional. For the PolyPhen-
based prediction, possibly or probably protein-damaging SNPs
were considered functional, and SNPs predicted to be benign
were considered nonfunctional.
For estimating the relationship between MAF and the propor-
tion of predicted protein-disturbing SNPs among nsSNPs, the
nsSNPs were binned into 20 categories deﬁned byMAF increments
of 2.5%. For each MAF category, we computed the proportion of
SNPs predicted to be protein disturbing. To compareMAF distribu-
tions for different types of SNPs, these were also were binned into
20 groups deﬁned by MAF increments of 2.5%.The ARadical and Conservative Missense Mutations
To stratify amino acid substitutions into radical and conservative,
we adopted the classiﬁcation system used by Dagan et al.39 In
brief, all amino acids were subdivided into three groups according
to their charge: positive (R, H, and K), negative (D and E), and un-
charged (A, N, C, Q, G, I, L, M, F, P, S, T, W, Y, and V). The amino
acids were further subdivided by volume and polarity: special (C),
neutral and small (A, G, P, S, and T), polar and relatively small (N,
Table 1. Counts of SNPs in Different MAF Categories in the
HapMap Data Set
Population MAFa
Type of SNP
Intronic S B Pos.D. Prob.D.
CEPH 0–0.025 38755 5626 4675 1584 987
CEPH 0.025–0.05 5778 571 370 109 51
CEPH 0.05–0.075 5580 462 403 82 40
CEPH 0.075–0.1 5262 458 317 74 38
CEPH 0.1–0.125 5402 414 300 52 34
CEPH 0.125–1.15 5217 355 280 57 27
CEPH 0.15–0.175 5182 332 272 48 32
CEPH 0.175–0.2 5320 341 214 43 33
CEPH 0.2–0.225 5293 286 235 55 34
CEPH 0.225–0.25 5082 296 206 37 26
CEPH 0.25–0.275 5181 297 225 54 22
CEPH 0.275–0.3 5097 268 237 45 24
CEPH 0.3–0.325 5213 299 210 35 16
CEPH 0.325–0.35 4981 304 236 36 19
CEPH 0.35–0.375 5124 243 197 34 20
CEPH 0.375–0.4 5054 277 199 36 19
CEPH 0.4–0.425 5038 251 164 38 25
CEPH 0.425–0.45 5181 240 171 46 26
CEPH 0.45–0.475 5190 271 200 26 26
CEPH 0.475–0.5 5155 223 212 31 13
Total 138085 11814 9323 2522 1512
Type of SNP
Population MAFa Intronic S B Pos.D. Prob.D.
Yoruba 0–0.025 33463 4650 4230 1475 930
Yoruba 0.025–0.05 7351 745 512 135 72
Yoruba 0.05–0.075 6903 618 447 92 57
Yoruba 0.075–0.1 6521 542 369 84 54
Yoruba 0.1–0.125 6404 554 309 67 31
Yoruba 0.125–1.15 5950 498 368 70 34
Yoruba 0.15–0.175 5952 400 312 74 44
Yoruba 0.175–0.2 5804 417 263 42 20
Yoruba 0.2–0.225 5397 356 212 42 26
Yoruba 0.225–0.25 5311 389 232 35 28
Yoruba 0.25–0.275 5174 338 221 55 20
Yoruba 0.275–0.3 4996 317 211 33 30
Yoruba 0.3–0.325 4928 282 218 32 21
Yoruba 0.325–0.35 4757 247 196 28 13
Yoruba 0.35–0.375 4527 244 178 33 24
Yoruba 0.375–0.4 4614 236 187 36 22
Yoruba 0.4–0.425 4560 266 175 29 19
Yoruba 0.425–0.45 4532 262 177 36 23
Yoruba 0.45–0.475 4352 263 166 40 16
Yoruba 0.475–0.5 4548 226 169 27 15
Total 136044 11850 9152 2465 1499
S, synonymous; B, benign; Pos.D., possibly damaging; and Prob.D., proba-
bly damaging SNPs.
a In each MAF category, the upper limit was included and the lower limit
was excluded, e.g., 0.45–0.475 includes all SNPs with 0.45< MAF% 0.475.merican Journal of Human Genetics 82, 100–112, January 2008 101
D, Q, and E), polar and relatively large (R, H, and K), nonpolar and
relatively small (I, L, M, and V), and nonpolar and relatively large
(F, W, and Y). Any substitutions that moved an amino acid from
one category to another were considered radical, whereas substitu-
tions that did not change amino acid category were classiﬁed as
conservative. We performed separate analyses for radical (totaling
3695) and conservative (totaling 2463) substitutions.
Statistical Analysis
Spearman’s nonparametric correlation was used for estimation of
the association between MAF and the proportion of nsSNPs
predicted to be protein disturbing, P(F). We used logarithmic
regression, PðFÞ ¼ a,lnðMAFÞ þ b, and linear regression, PðFÞ ¼
a,MAF þ b, to ﬁt the binned data by the least-squares method.
Statistical power was computed by assuming a case-control
design with independent cases and controls, and the data were
analyzed by an uncorrected chi-square test.40 The sample size
was varied from 100 to 10,000 in increments of 100. The MAF
was assumed to vary from 0 to 0.5 in increments of 0.025. Domi-
nant and recessive models with genotypic risk ratios of 1.3 and 1.5
were considered. Critical p values of 0.05 were used.
Adjusting the Proportion of Functional nsSNPs
by Sensitivity and Speciﬁcity of PolyPhen
The observed proportion of functional nsSNPs depends on the
true proportion and on the sensitivity and speciﬁcity of the
Table 2. Counts of SNPs of Different MAF Categories
in the SeattleSNPs Data Set
Population MAFa
Type of SNP
Intronic S B Pos.D. Prob.D.
ED 0–0.05 20239 513 346 95 73
ED 0.05–0.1 2126 53 32 9 4
ED 0.1–0.15 1664 44 25 5 5
ED 0.15–0.2 1277 18 17 4 1
ED 0.2–0.25 1236 31 18 1 6
ED 0.25–0.3 1275 32 17 5 0
ED 0.3–0.35 952 17 19 0 0
ED 0.35–0.4 818 18 17 0 2
ED 0.4–0.45 981 22 9 1 0
ED 0.45–0.5 937 16 6 1 2
Total 31505 764 506 121 93
Type of SNP
Population MAFa Intronic S B Pos.D. Prob.D.
AD 0–0.05 15722 370 292 81 59
AD 0.05–0.1 4732 122 56 16 13
AD 0.1–0.15 2488 68 35 6 5
AD 0.15–0.2 1747 40 33 7 3
AD 0.2–0.25 1717 49 17 2 5
AD 0.25–0.3 1243 24 20 3 2
AD 0.3–0.35 1106 26 16 3 1
AD 0.35–0.4 812 13 9 0 3
AD 0.4–0.45 943 28 13 1 1
AD 0.45–0.5 995 24 15 2 1
Total 31505 764 506 121 93
ED, European descent; AD, African descent; S, synonymous; B, benign;
Pos.D., possibly damaging; and Prob.D., probably damaging SNPs.
a In each MAF category the upper limit was included and the lower limit was
excluded, e.g., 0.45–0.5 includes all SNPs with 0.45 < MAF% 0.5.102 The American Journal of Human Genetics 82, 100–112, Januarypredicting method. Let Ptf be the true proportion of functional
nsSNPs in a given MAF category (bin) and Pobs be the observed
proportion of functional SNPs. For PolyPhen, the probability of
identifying a SNP as functional when it is functional (sensitivity)
is ~0.82, and the probability of identifying a SNP as functional
when it is nonfunctional (1 speciﬁcity) is ~0.08.38 The observed
proportion of functional SNPs, given that the true proportion is
Ptf, can be computed as follows: Pobs ¼ Ptf$0.82 þ (1  Ptf) 0.08;
therefore, Ptf ¼ (Pobs  0.08)/0.74. We used the latter equation to
adjust the estimated proportion of protein-disturbing nsSNPs for
the sensitivity and speciﬁcity of PolyPhen. We were not able to
ﬁnd estimates of speciﬁcity and sensitivity for SIFT and, therefore,
were not able to provide a similar correction for the proportion of
SNPs predicted to be functional by SIFT.
Results
Distribution of SNPs by MAF
The International HapMap Project26 and the dbSNP data-
base27,28 were used as sources of data. We retrieved data
from the International HapMap Project on the distribution
of MAFs in coding regions (rel22_Build36). A separate
analysis was run with SNPs data from the Encyclopedia
of DNA Elements (ENCODE) project.32 The ENCODE
data were obtained by sequencing ten 500 kb regions in
48 individuals (16 from each group). The novel SNPs de-
tected by sequencing were then genotyped in all HapMap
DNA samples.32
We compared the proportion of SNPs in different MAF
categories by using the ENCODE SNPs and all the HapMap
SNPs (Figure 1). The total number of SNPs in the ENCODE
data set was 93,149, and the total number of SNPs in
the phase II HapMap database (rel22_NCBI_Build36) was
3,839,363 for the Centre d’Etude du Polymorphisme
Humain (CEPH) population and 3,782,818 for the Yoruba
population. Only parents were included in the analysis.
Figure 1. Distribution of SNPs from the Encyclopedia of DNA
Elements and of All SNPs Reported in the International HapMap
Database by Minor Allele Frequency
The distribution of encyclopedia of DNA elements (orange) and all
single-nucleotide polymorphisms (SNPs) reported in the Interna-
tional HapMap database (blue) by minor allele frequency (MAF)
are shown. All SNPs regardless of their functional category were
included in the analysis.2008
SNPs were included in the analysis regardless of their
MAF and binned into 20 MAF groups. We found that the
proportion of SNPs with MAF <5% in the ENCODE data
set (0.50 5 0.01) was signiﬁcantly greater than the pro-
portion of rare SNPs in the entire HAPMAP data set
(0.38 5 0.01). Because ENCODE SNPs were identiﬁed by
direct sequencing of a constant sample size, they are
expected to be less biased than phase II HapMap SNPs for
which the initial SNP discovery phase reﬂects a combi-
nation of pooled sequencing and direct sequencing
conducted on varying number of subjects; this result
strongly suggests that the majority of SNPs in the human
genome have MAF <5%. The limited number of 45
individuals sequenced by ENCODE further suggests that
the actual proportion of rare SNPs could be greater
than 50%.
Figure 2. Distribution of Intronic
Ratios and MAFs for Various Types of
the HapMap SNPs in Coding Regions of
the Human Genome: S, B, Pos.D., and
Prob.D. SNPs
(A)–(C) show the CEPH (Europeans) sample;
(D)–(F) show the YRI (Africans) sample. (A)
and (D) show intronic ratios for synony-
mous SNPs (S), nonsynonymous SNPs pre-
dicted to be benign (B), nsSNPs predicted
to be possibly damaging (Pos.D.), and
nsSNPs predicted to be probably damaging
(Prob.D.). Absolute numbers of S, B,
Pos.D., and Prob.D. SNPs varied drastically,
thereby making direct comparisons of
intronic ratios difficult. For visual clarity,
we scaled the average ratios to 1 by anchor-
ing the distributions by their rightmost
parts (i.e., 0.4–0.5). Standard errors (SEs)
are shown for S and Prob.D. SNPs. (B) and
(E) show the distribution of SNPs with
0–0.025 MAFs. The proportion of SNPs in
the 0–0.025 MAF category is shown sepa-
rately because it was much greater than
proportions in the other categories. MAF
was portioned into 20 bins by a 2.5%
step. (C) and (F) show the proportion of
SNPs in MAF >0.025 categories.
MAF and the Intronic Ratio Based
on HapMap Data
The ratio of absolute numbers of SNPs
of speciﬁc categories reported in the
database (e.g., nsSNPs) to the absolute
number of intronic SNPs (here re-
ferred to as the intronic ratio) can be
used as a relative measure of selec-
tion.35 A constant intronic ratio across
different MAF categories suggests that
there are no differences in intensity of
selection among MAF categories. An
increased intronic ratio at low MAFs suggests purifying se-
lection against nsSNPs. We computed intronic ratios for
20MAF categories from theHapMapdata for (1) nonsynon-
ymous SNPs predicted to be probably damaging protein
structure and function damaging (Prob.D.), (2) nonsynon-
ymous SNPs predicted to be possibly damaging protein
structure and function damaging (Pos.D.), (3) nonsynony-
mous SNPs predicted to be benign (B), and (4) synonymous
SNPs (S). We used PolyPhen for prediction of functional-
ity.38 The list of nsSNPs with prediction of functionality
can be found in Table S1 available online.
Figures 2A and 2D show the intronic ratios for nsSNPs
for CEPH (Europeans) and YRI (Africans) samples corre-
spondingly. We found that the intronic ratio was nearly
constant for nsSNPs withMAF>20%. However, for nsSNPs
with MAF <10%, and especially for SNPs with MAF <5%,The American Journal of Human Genetics 82, 100–112, January 2008 103
the intronic ratio increased sharply, suggesting a strong
effect of purifying selection. We further found that the
relationship between MAF and intronic ratio for benign
SNPs was similar to that for synonymous SNPs. We also
found an increased intronic ratio at lowerMAFs for Prob.D.
and Pos.D. SNPs, suggesting stronger purifying selection
against these categories. The intronic ratio was increased
for rare synonymous and benign SNPs for HapMap data
set, but this effect could reﬂect a bias against genotyping
of rare intronic SNPs.
Comparison of MAF Distributions of SNPs of Different
Functional Types in the Coding Region Based
on HapMap Data
Not all SNPs reported in the database are true polymor-
phisms; according to some studies, the false-discovery
rate might be as high as 10%.33,34 To decrease the propor-
tion of false discoveries in our sample, we used only fre-
Figure 3. Distribution of Intronic
Ratios and SNPs by MAF Categories,
SeattleSNPs Database
(A)–(C) show European descent; (D)–(F)
show African descent. (A) and (D) show
intronic ratios for synonymous SNPs (S),
nonsynonymous SNPs predicted to be be-
nign (B), nsSNPs predicted to be possibly
or probably damaging (Pos.D./Prob.D.).
The distributions were anchored by their
rightmost parts similarly as in Figure 2.
SEs are shown for S and Pos.D./Prob.D.
SNPs. (B) and (E) show the distribution
of SNPs with 0–0.05 MAFs. Proportions of
SNPs in 0–0.05 MAF category are shown
separately because they were much greater
than proportions in the other categories.
(C) and (F) show proportions of SNPs in
MAF >0.05 categories.
quency-validated SNPs. Thus, 6158
frequency-validated nsSNPs from
3912 genes were used in the analysis.
We found that the MAF distribu-
tion of the probably damaging SNPs
(SNPs that are most likely to disturb
protein structure and function) was
left-shifted in CEPH and YRI samples
(Figures 2B, 2C, 2E, and 2F). There
was also a trend for SNPs that were
likely to be functional to have lower
MAF. The difference between SNP cat-
egories suggests that purifying selec-
tion shapesMAF distributions of SNPs
in the coding region. We excluded
intronic SNPs from this analysis of
MAF distributions because of a bias
against genotyping intronic SNPs; in-
tronic SNPs are less likely to be chosen
for genotyping by HapMap compared with the SNPs in the
coding regions.
Intronic Ratios and MAF Distributions
Based on SeattleSNPs Data
Figures 3A and 3D show the intronic ratios for SNPs identi-
ﬁed by sequencing of genomic DNA (SeattleSNPs database)
for thesubjectsofEuropeanandAfricandescentcorrespond-
ingly. We found that in European subjects in the group of
rare SNPs (MAF%0.05) the intronic ratio for Pos.D./Prob.D.
SNPs was 3.745 0.18, which was signiﬁcantly higher com-
pared to the intronic ratio for both synonymous (1.23 5
0.14) and benign (1.41 5 0.17) SNPs (t test for S versus
Pos.D./Prob.D. SNPs was 9.6, N ¼ 32,269, p << 0.001). No
signiﬁcant differences were detected between benign and
synonymous SNPs. Intronic ratios for these two types of
SNPs were constant across MAF categories. Similar results
wereobtained for the subjectsofAfricandescent (Figure3D).104 The American Journal of Human Genetics 82, 100–112, January 2008
Figure 4. Proportion of Nonsynony-
mous Single-Nucleotide Polymorphisms
Predicted to be Protein Damaging Plot-
ted against Minor Allele Frequency
Each point represents the proportion of
functional nsSNPs in a given MAF category.
(A) shows the proportion predicted by the
PolyPhen method. Dark solid lines are the
logarithmic-regression curves. The orange
line is the regression curve adjusted for
PolyPhen’s sensitivity and specificity (see
Material and Methods for details). Vertical
bars represent SEs computed on the basis
of the multinomial distribution. (B) shows
the proportion predicted by the sorting
intolerant from tolerant (SIFT) method.Figures 3B, 3C, 3E, and 3F show the distribution of MAF
for intronic, synonymous, benign, and damaging SNPs
among Europeans and Africans correspondingly. For Euro-
peans, we found that the proportion of Pos.D./Prob.D.
SNPs was highest in MAF 0–0.05 (0.785 0.02); the propor-
tion of benign SNPs was not signiﬁcantly different from
the proportion of synonymous SNPs, with 0.68 5 0.02
and 0.67 5 0.02, correspondingly. The proportion of in-
tronic SNPs in the MAF category 0–0.05 (0.64 5 0.01)
tended to be lower compared to that of benign and synon-
ymous SNPs. Similar results were obtained for the subjects
of African descent (Figures 3E and 3F).
Relationship between MAF and the Proportion
of Protein-Damaging SNPs
We analyzed the relationship between the MAF and the
proportion of nsSNPs predicted to be protein damaging
by PolyPhen (Figure 4A) (Spearman’s correlation coefﬁ-
cient was 0.75, n ¼ 25, and p < 0.001). The logarithmic
regression of the observed proportion of functional nsSNPs
on the MAF was
_
PðFÞ ¼ 0:04,lnðMAFÞ þ 0:17. In this
case, logarithmic regression explained 79% of the variation
and also ﬁtted the data better than did linear regression,
which explained 56% of the observed variation. For the
PolyPhen method, we also adjusted the prediction curve
by PolyPhen sensitivity and speciﬁcity as described in the
Material and Methods.
A similar result was obtained for the proportion of the
nsSNPs predicted to be protein damaging by sorting intol-
erant from tolerant (SIFT).41 MAF was negatively correlated
with the proportion of SIFT-predicted protein-damaging
nsSNPs (Spearman’s nonparametric correlation coefﬁcient
was0.73, n¼ 25, and p< 0.001) (Figure 4B). Logarithmic
regression explained 74% of the observed variation and
ﬁtted the data better than did linear regression, which
explained only 54% of the variation.
Obviously MAF is not the only indicator of the probabil-
ity that a SNP is functional. The category of SNP is also as-
sociated with its functionality. For example, synonymous
SNPs are less likely to be functional compared with nsSNPs.
If we consider SNPs from a speciﬁc functional categoryThe Am(e.g., synonymous SNPs), the overall probability for SNPs
from that category to be functional will vary from that
for SNPs in other categories. Within a category, however,
one can expect to see the same inverse relationship be-
tween MAF and the proportion of functional SNPs because
purifying selection will drive down MAFs of functional
SNPs. We compared the proportion of SNPs predicted to
be functional separately for nsSNPs producing radical
mutations and for nsSNPs producing conservative mis-
sense mutations (Figure 5). A radical missense mutation
replaces wild-type amino acid with an amino acid that is
chemically different, whereas conservative mutations re-
place wild-type amino acids with chemically similar ones.
Therefore, the overall proportion of functional substitu-
tions is expected to be greater among radical missense
mutations than among conservative ones. We found that
the overall probability that a SNP is functional is almost
two times greater for nsSNPs producing radical missense
mutations than for nsSNPs producing conservative mis-
sense mutations. We also found that the logarithmic-
regression curves of the proportion of functional SNPs on
MAF were very similar for these two types of SNPs, suggest-
ing that the same factors inﬂuence MAF-functionality rela-
tionships for SNPs having different prior probabilities to
be functional.
Statistical Power to Detect Effects of Rare SNPs
Statistical power depends on many factors including effect
size (usually expressed as the odds ratio [OR]), sample size,
mode of inheritance (e.g., dominant or recessive), and
MAF. The statistical power is generally lower for rare SNPs
than for common SNPs of a similar effect size. Figure 6
illustrates the relationship between statistical power and
the needed sample size for a series of SNPs with MAF
%5%, assuming a dominant model. For a SNP with OR ¼
1.5 and MAF ¼ 5%, a sample size of 1862 (931 cases and
931 controls) would be needed to achieve 80% statistical
power to detect the effect at a p level of 0.05. For a SNP
with OR ¼ 1.5 and MAF ¼ 2.5%, the required sample size
would be 3420, and for MAF ¼ 1%, the required sample
size would exceed 8120. The power is very sensitive toerican Journal of Human Genetics 82, 100–112, January 2008 105
the OR. With OR ¼ 2 and MAF ¼ 5%, the required sample
size is 580 (290 cases and 290 controls). For the same OR
and MAF ¼ 2.5%, the required sample size is 1050, and
for MAF¼ 1%, the required sample size is 2450. This shows
that when the effect of rare SNPs is relatively high
(OR R2), there is sufﬁcient power to detect the effect of
a rare SNP, even for a modest sample size of 1000.
Power to Detect a True Association
Not all nsSNPs are functional and impart a potential to be
disease associated. Statistical power predicts the probabil-
ity that a SNP will be detected as signiﬁcant conditional
on its being functional, which we denote as P(S,F). Thus
the joint probability that a SNP is signiﬁcant and func-
tional is expressed as P(S,F) ¼ P(SjF)P(F), for which P(S,F)
Figure 5. Conservative versus Radical Amino Acid Substitu-
tions
Proportions of functional SNPs among radical (blue line) and con-
servative (green line) amino acid substitutions are shown. Vertical
bars represent SEs. Predictive curves (gray) and equations are
shown separately for radical and conservative substitutions.106 The American Journal of Human Genetics 82, 100–112, Januaryis the joint probability that a SNP is signiﬁcant and func-
tional, P(SjF) is the power, and P(F) is the probability that
a SNP is functional. If we assume P(F) ¼ 1, we will obtain
the statistical power that is usually used to design case-con-
trol association studies. Our analysis demonstrated, how-
ever, that the probability that a SNP was functional was
negatively correlated with MAF, whereas the probability
that a SNP will be detected as signiﬁcant was positively cor-
related with MAF. In other words, there is a trade-off
between gain in probability of detection and loss in the
proportion of functional SNPs when MAF increases. To
account for this inverse relationship, we used the P(S,F)
¼ P(SjF)P(F) formula to compute the joint probability
that a SNP is functional and will be detected as signiﬁcant.
We deﬁned this joint probability as the power to detect
a true association (PDTA), which predicts statistical power
when P(F) s 1 but depends on MAF.
Figure 7 gives a quantitative example of computing
PDTA and shows that PDTA ﬁrst increases, reaches a maxi-
mum, and subsequently decreases. The MAF at which
PDTA is maximal is an important parameter for the design
of a case-control study because it maximizes the chance
that a functional SNP will be detected as signiﬁcant. The
MAF at which PDTA is maximal was denoted as the most
powerful MAF (mpMAF).
For this and other computations of PDTA, we used a con-
servative assumption that the OR did not depend on MAF
and that only the proportion of functional SNPs did. How-
ever, rare SNPs might disturb gene function to a greater
extent than common SNPs and therefore have higher
ORs. If this is true, statistical power should increase with
the increasing rarity of SNPs compared with a model
with a constant OR.
Like statistical power, PDTA depends on sample size, ef-
fect size, inheritance model, and MAF. PDTA’s dependence
on the sample size is important because sample size is one
of the key parameters in case-control-study design. We
computed PDTAs for a set of sample sizes and MAFs. Reces-
sive and dominant models were analyzed (Figure 8). Ridges
on the PDTA surfaces mark MAFs at the mpMAF, where the
PDTA is maximal. The mpMAF ridge was much sharper for
the dominant model than the recessive model, suggesting
that a given deviation in MAF from the mpMAF leads to
a much stronger decrease in the PDTA in the dominant
model than in the recessive model.Figure 6. Relationship between Statis-
tical Power and Needed Sample Size
The model shows a dominant causal single-
nucleotide polymorphism with a minor
allele frequency (MAF) %5%. (A) shows
OR ¼ 1.5, and (B) shows OR ¼ 2.0. We
used a 5% significance level. The power
calculations were performed on the basis
of the assumption that only one SNP is
being typed (no corrections for multiple
testing).2008
Figure 7. Example of Computing Proba-
bility to Detect True Association and
Most Powerful Minor Allele Frequency
Study of single-nucleotide polymorphisms
in a dominant model of inheritance with
300 cases and 300 controls. An OR ¼ 1.5
was assumed. In (A), the red line shows
the dependence of the statistical power
on minor allele frequency (MAF), and the
blue line shows the predicted proportion
of functional SNPs P(F), predicted by for-
mula 1. (B) shows the dependence of
PDTA on MAF. The mpMAF is marked by
the vertical line, which indicates ~0.22 in
this case.The results presented in Figure 8 suggest an inverse
relationship between mpMAF and sample size. We further
investigated the relationship between mpMAF and sample
size by computing PDTAs and mpMAFs for dominant and
recessive models with ORs of 1.3 and 1.5. We found that
for all scenarios, mpMAF decreased as the sample size in-
creased (Figure 9). For the dominant model, with a modest
OR of 1.5, mpMAF was <5% when the sample size was
R1500. For the recessive model, with an OR of 1.5,
mpMAF was <5% when the sample size was R6000. We
also found that, given the same sample size, mpMAF was
higher for lower ORs (for a given sample size, mpMAF
increased as OR decreased). mpMAFs were higher for the
recessive model than for the dominant one.
Discussion
Genetic Architecture of Common Disease
The number and penetrance of alleles affecting disease risk,
i.e., the genetic architecture of a disease, directly affect the
strategy for identifying polymorphisms that modulate dis-
ease susceptibility. Few theoretical analyses of the genetic
architecture of common human diseases have been pub-
lished.42–44 The expected number and distribution of dis-
ease alleles in the population depend on mutation rate, se-
lection, and population demography. Mutation rate in this
case means mutation rate for disease alleles. This rate de-
pends on the number of the potential sites for deleterious
disease-causing mutations in the disease-related gene andThe Amalso on the number of disease genes in the genome. The dis-
ease mutation rate is higher than the nucleotide-substitu-
tion rate, which is estimated as ~108 mutations per nucle-
otide per generation.45,46 By assuming that (1) the disease
mutation rate is ~106 disease-associated mutations per
disease locus, that (2) a single dramatic expansion of the
human population occurred approximately 70,000 years
ago, and (3) that no genetic drift has occurred, Reich and
Lander44 concluded that one or two common polymor-
phisms can explain genetic susceptibility to common hu-
man diseases. However, the analysis probably oversim-
pliﬁes the real situation because it assumes no bottlenecks
or effects of genetic drift for susceptibility mutations.
Pritchard,42 who used stochastic modeling to estimate the
level of genetic diversity for common diseases, concluded
that ‘‘it is unlikely that any single mutation will constitute
a large fraction of the susceptible class.’’ Simulation analysis
of the genetic architecture of common human diseases by
Peng and Kimmel47 demonstrated that mutation spectra
are expected to be simple for a single-locus model. If, how-
ever, a commondisease is caused bymultiple loci, then a di-
verse allelic spectrum with rare causal alleles is predicted.
Recently, Kryukov et al.48 combined analysis of muta-
tions causing humanMendelian diseases, of human-chim-
panzee divergence data and the data on human genetic
variation, and found that ~53% of new missense muta-
tions have mildly deleterious effects. The authors also
found that up to 70% of low-frequency missense alleles
are mildly deleterious. Kotowski et al.49 used sequencing
to identify rare polymorphisms in the PCSK9 geneFigure 8. Dependence of the Probabil-
ity to Detect a True Association on Minor
Allele Frequency and Sample Size
Equal sample sizes for cases and controls
were assumed, and the total sample size
is shown. OR ¼ 1.5 in both the (A) reces-
sive and (B) dominant models.erican Journal of Human Genetics 82, 100–112, January 2008 107
controlling plasma levels of low-density lipoprotein cho-
lesterol. The authors identiﬁed several rare nsSNPs with
strong phenotypic effects on cholesterol level, providing
support for the importance of including rare sequence
variants in association studies.
As noted above, the major parameter that deﬁnes the
diversity of disease alleles in a population is mutation
rate per gene per generation. Unfortunately, there are no
reliable estimates of this parameter. Reich and Lander44 es-
timated amutation rate for disease-associated mutations as
3.2 3 106. Pritchard’s42 estimate ranged from 2.5 3 106
to 1.33 104. Estimates based on the analysis of mutations
reported in the human gene mutation database50,51 sug-
gest that the mutation rate for slightly deleterious muta-
tions is ~105. If the mutation rate for susceptibility alleles
is ~105 or higher, it is likely that the genetic architecture
of common diseases is diverse and that there are many sus-
ceptibility alleles in the population. Another factor that
affects the genetic architecture of common disease is the
number of genes contributing to genetic control of disease
susceptibility. If several genes affect disease susceptibility,
it is likely that many polymorphic susceptibility variants
underlie disease risk. For many common human diseases,
there are probably many susceptibility loci.
Cancer is a good example of a common disease with
many loci affecting disease susceptibility. The development
of cancer is a multistage process that involves genes impor-
Figure 9. Predicted Dependence of Most Powerful Minor Allele
Frequency on the Sample Size
Recessive (blue lines) and dominant (red lines) models were
assumed. The sample comprises equal numbers of cases and con-
trols, and the total size is shown. (A) shows OR ¼ 1.3. (B) shows
OR ¼ 1.5.108 The American Journal of Human Genetics 82, 100–112, Januarytant for cell-cycle control, cell proliferation, apoptosis, an-
giogenesis, and other cellular-pathway functions. There-
fore, it is plausible to suggest that many causal SNPs
modulate cancer susceptibility. We suggest that sdSNPs,
which are subjected to weak purifying selection, are the
major players in genetic control of susceptibility to many
common diseases. However, cancer is predominantly a dis-
ease of late age when reproduction is mostly completed.
Therefore, natural selection could not have affected the fre-
quencies of alleles in cancer genes purely on the basis of
their effect on cancer risk. On the other hand, genes that af-
fect the risk of cancer did not evolve merely as cancer-risk
genes; this function emerged relatively recentlywith the re-
cent increase in life expectancy. Cancer suppressors and
oncogenes play an important role in the control of the
cell cycle, apoptosis, angiogenesis, and development pro-
cesses that are under pressure of purifying selection. There-
fore, protein-damaging mutations in cancer-related genes
would be expected to be under the pressure of purifying
selection and thus to have a lower population frequency.
SdSNPs and MAF
SdSNPs are not eliminated from the population because
the reduction in ﬁtness they cause is too small. If we as-
sume that the observed population frequency of sdSNPs
is a result of equilibrium between purifying selection and
mutations, then the intensity of purifying selection
against sdSNPs can be estimated on the basis of the classi-
cal formula q ¼ m/hs, where q is the equilibrium frequency
of a mutant allele, m is the mutation rate per generation,
h is the dominance coefﬁcient, and s is selection coefﬁ-
cients.52 Accepting that m is ~108 (see 45 and 46) and h
is ~0.1 (see 53) and assuming q ¼ 0.05, the selection coefﬁ-
cient will be ~106  105. Genetic drift is expected to
affect the population frequency of deleterious alleles when
s << 1/Ne, where Ne is the effective population size. There
is general agreement that for the human population, Ne
is ~104.54 Therefore, it follows that selection and drift
play a role in the distribution of MAFs for sdSNPs. This
might also explain the existence of causal SNPs with
high MAF for some common human diseases.11–14
The high prevalence of SNPs with low MAF among
nsSNPs, higher intronic ratios for rare SNPs, and the in-
verse relationship between the proportion of protein-dam-
aging SNPs and MAF strongly suggest that functional SNPs
are under weak purifying selection and therefore tend to
have lower MAFs. With respect to intronic ratio, we ac-
knowledge that the increase of intronic ratio for low MAF
can be a result of genotyping bias against intronic SNPs, es-
pecially those with low MAF when HapMap data are ana-
lyzed. It is also possible that some synonymous SNPs can
be functional because of their effect on splicing or codon
usage.55–58 Recent studies demonstrated that synonymous
SNPs undergo a slight purifying selection.59,60
Results of our study are in agreement with other reports
on the negative correlation between MAF and the propor-
tion of functional SNPs.35,61 Cargill et al.35 analyzed 3922008
SNPs located in the coding regions of 106 genes and found
that the proportion of nsSNPs was highest among SNPs
with a low MAF. Wong et al.61 observed a similar relation-
ship between MAF and the proportion of nsSNPs predicted
to be protein damaging. The results of our analysis of the
relationship between MAF and the proportion of func-
tional SNPs are based on a much larger number of SNPs
than that previously studied, and they are in agreement
with previous studies and provide a more comprehensive
picture of the relationship between MAF and the propor-
tion of protein-damaging SNPs.
In this study, we used two data sets to retrieve MAF data:
the HapMap and SeattleSNPs. The HapMap sample size is
much larger compared to the SeattleSNPs sample size.
However, the HapMap database is likely to underreport
intronic SNPs, especially those with low MAF. This bias is
probably the major source of the increased intronic ratio
for benign and synonymous SNPs at low MAF category
(Figures 2A and 2D). The intronic ratio was constant for
benign and synonymous SNPs when the SeattleSNPs data
were analyzed (Figures 3A and 3D). We cannot exclude
also that a weak purifying selection against benign and
synonymous SNPs might as well have contributed to the
increased intronic ratio for benign and synonymous
SNPs as suggested from the analysis of MAF distributions
(Figures 3B, 3C, 3E, and 3F).
Our analysis was based on the assumption of the inde-
pendence of SNPs. This is violated to some extent due to
linkage disequilibrium (LD) between SNPs. If SNPs that
are in strong LD tend to have similar MAFs, then the num-
ber of independent observations will be lower than the
number of SNPs in the analysis. It is difﬁcult, however, to
imagine a biological phenomenon that can link MAFs of
the SNPs on the basis of their position. We are not aware
of any studies that address this phenomenon on a ge-
nome-wide level. Nevertheless, we have addressed this
concern by analysis of singletons—single SNP per gene.
In our data set, ~47% of nsSNPs are singletons. Those
SNPs are unlikely to be in strong LD unless the genes are
located very close to one another. The analysis conducted
with singleton SNPs yielded very similar results in terms of
MAF distribution between benign and possibly and proba-
bly damaging SNPs (data not shown).
Most SNPs in the Human Genome Are SNPs
with MAF <5%
The MAF distribution of SNPs from the International Hap-
Map Project shows that more than 40% of SNPs have MAF
<5%. Because the International HapMap Project preferen-
tially targeted common SNPs, the real proportion of rare
SNPs is deﬁnitely higher than 40%. We estimate, on the
basis of ENCODE data, that ~60% of SNPs have MAF
<5%. This estimate is supported by Wong et al.,61 who
sequenced 114 genes from the Environmental Genome
Project.62,63 A total of 64, 38, and 12 genes were sequenced
in 44, 90, and 450 individuals, respectively. Across this
gene set, each base was evaluated on an average sampleThe Asize of 84 individuals. The authors found that SNPs with
MAF <5% constituted >60% of the total number of
SNPs. If we include SNPs with MAF<< 1% in our analysis,
the proportion of rare SNPs will be even higher. On the ba-
sis of practical considerations, we suggest that rare SNPs be
considered those with MAFR0.5% and%5%. Indeed, cur-
rent sample sizes do not allow effective detection and com-
parison of frequencies of SNPs with MAF <0.5%. Another
reason for setting the lower limit at 0.5% for rare SNPs is
that very rare SNPs would need extremely high penetrance
(similar to that for dominant Mendelian mutations) to
greatly affect the prevalence of disease.
Conclusions
Wehypothesized that interindividual variation in suscepti-
bility to common diseases is mainly caused by sdSNPs in
genes implicated in disease pathways. Our hypothesis sug-
gests that causal SNPs have low MAF; however, the low
population frequency of the causal SNPs is compensated
for by the large number of such SNPs in the genome. The
deleterious effect of sdSNPs is deleterious enough to impair
gene function and increase disease risk. It is, however, not
strong enough for selection to totally eradicate them from
the population (genetic drift, founder effects, and popula-
tion bottlenecks are factors that help retain sdSNPs).
The principal difﬁculty in explaining common diseases
by sdSNPs is that sdSNP might be too rare to explain the
observed disease’s prevalence. The high proportion of
rare SNPs in the genome, however, can counter the low
MAF of the causal SNPs. According to the Build 126 of
the dbSNP database, there are >56,000 nsSNPs in the
human genome. The real number of nsSNPs is probably
higher because rare SNPs are underreported. If we assume
that there are twice as many nsSNPs as there have been
reported today64 and half of these nsSNPs are slightly del-
eterious with MAF <5%, and that there are ~24,000 genes
in the human genome, there should be two to three rare
sdSNPs per gene. The real number might be higher still
because we did not consider promoter SNPs or SNPs located
in sites important for splicing. This suggests that the effect
of rare sdSNPs on disease prevalence can be substantial.
Our many rare SNPs hypothesis suggests that targeting
rare SNPs in large case-control association studies has
more power to detect causal SNPs than does targeting com-
mon SNPs.We found that there is a negative correlation be-
tween sample size andmpMAF, and this explains whymost
of the causal SNPs identiﬁed to date are common. Indeed,
studies that have identiﬁed (and conﬁrmed) causal SNPs
used sample sizes of between 500 and 1000 subjects; for
such sample sizes, the mpMAF ranges from 8% to 30%, de-
pending on the OR and type of model. For case-control
studieswith sample sizes ofR2000, thempMAF is expected
to be <5% (at least for the dominant model), suggesting
that targeting rare SNPs in large studies might be a better
strategy for identifying causal SNPs than targeting common
SNPs, which are less likely to be functional. We conclude
that targeting SNPs with MAF <5% in large case-controlmerican Journal of Human Genetics 82, 100–112, January 2008 109
studies is a sound strategy to identify causal SNPs. Direct se-
quencing of candidate regions in a subset of cases and con-
trols (e.g., 100 cases and 100 controls) can be used to iden-
tify rare SNPs. Those rare SNPs should be then genotyped
in the whole sample with custom-designed chips.
We believe that targeting rare potentially functional
SNPs (nsSNPs and SNPs located in promoter regions) can
be a more appropriate strategy to understand the genetic
architecture of many complex diseases compared with
the strategy that targets common SNPs. Therefore, a practi-
cal recommendation from our analysis is the need for ge-
notyping rare SNPs, especially those from the coding and
promoter regions, into genotyping platforms. Another ap-
plication of our analysis relates to assigning priors in Bayes-
ian association analysis framework—SNPs can be assigned
different prior weights depending on their MAFs, with
higher weights being given to those with lower MAF.
In conclusion, we hypothesized that numerous rare
functional SNPs are major contributors to susceptibility
to common diseases, including cancer. The analysis of
joint probability that a SNP is functional and that it will
be detected as signiﬁcant in a case-control study demon-
strated that, for a given sample size, there is a MAF for
which this joint probability is maximal—the most power-
ful MAF. We found that the larger the sample size, the
lower the mpMAF, suggesting that for studies with large
sample sizes (5000 and higher) targeting rare SNPs will be
a better strategy for identifying causal SNPs than targeting
common SNPs.
Supplemental Data
One table is available at http://www.ajhg.org/cgi/content/full/82/
1/100/DC1/.
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